Abstract:Objective:Hypertrophic preconditioning (HP) was recently found to attenuate cardiac hypertrophy in the mouse. However, this mouse model of HP has encountered problems such as long thoracic exploration time and high mortality due to repeated thoracotomy and multiple banding/de-banding of the aorta, which restricts the in-depth study of HP in vivo. We intended to optimize the key aspects of establishment of HP and apply ultrasound biomicroscopy to non-invasively assess cardiac load to ensure stable and efficient model establishment.Methods:Male C57BL/6J mice (10-14 weeks old) were divided into hypertrophic preconditioning conventional operation group (C-HP, N=40), hypertrophic preconditioning optimized operation group (O-HP, N=40, with long thread buried under the chest skin, and releasing the banding knot by microscopic tweezers), transverse aortic constriction (TAC) group (TAC, N=20), and sham operation group (Sham, N=20). Four weeks after the last operation in each group, the surviving mice underwent ultrasound biomicroscopy and pathological examination to assess cardiac hypertrophy. Echocardiography was used to detect wall thickness and left ventricular inner diameter. After ultrasound examination, the mice were euthanized, hearts were excised, and heart weight/body weight ratio was measured. The pathological section was used to measure the cross sectional area of the myocardial cells and cardiac fibrosis.Results:In the process of de-banding and re-banding, O-HP significantly shortens the operation time and reduces the mortality rate compared with C-HP. Four weeks after re-banding, the survival rate of mice in the O-HP group was 67.5% (27/40), which was signficantly higher than that in the C-HP group of 37.5% (15/40) ( P=0.007). Non-invasive detection of blood flow in the aortic constriction by ultrasound biomicroscopy revealed that the peak velocity of blood flow at the banding site in the O-HP group and C-HP were similar in the key points of banding-de-banding-re-banding, suggesting that the optimization of the HP model does not affect the level of stress load in the heart. Compared with the Sham group, the ventricular wall of the TAC 4W group was conspicuously thickened, the heart function was impaired, the cross-sectional area of myocardial cells was significantly increased, and fibrosis was significantly enhanced. Re-TAC 4W significantly alleviated the above hypertrophic response. In addition, the expression of atrial natriuretic peptide and B type natriuretic peptide was decreased and the activation of ERK1/2 was reduced in the Re-TAC 4W group compared with the TAC 4W group. Conclusions:We have successfully established and assessed an optimized mouse model of HP. This model significantly shortens the time of surgery, significantly reduces the mortality rate of mice, can be non-invasively and serially detected for its cardiac pressure load status, and reveals that ERK1/2 may be a potential important signal factor related to HP. It provides an efficient and practical animal model for early intervention and drug screening studies of cardiac hypertrophy.

Optimized establishment and non-invasive evluation of a mouse model of cardiac hypertrophic preconditioning